Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies is a research paper published in Clinical Lung Cancer (2025). On theSindex it has a DataRank of 0.104. It has been cited 1 time.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.104
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: R01 CA249666
NCI NIH HHS
Grant: P30 CA008748
Cycle for Survival
National Institutes of Health
Puma Biotechnology
Memorial Sloan Kettering Cancer Center Marie-Josée and Henry R Kravis Center for Molecular Oncology
FWCI
0.73
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords